RxDoctor Payments Data

Matthew Voltz, DO

Sports Medicine · Wilmington, DENPI 1912215112

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Radius Health, Inc. at 57.0% of the total.

$831in general payments, 2019–2025

Across 38 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$474
  • Trice Medical, Inc.$81
  • Amgen$64
  • Eclipse Technology Solutions Inc.$50
  • Vertex$35
  • Fidia Pharma USA Inc.$33
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Radius Health, Inc.23$474
Trice Medical, Inc.1$81
Amgen4$64
Eclipse Technology Solutions Inc.1$50
Vertex2$35
Fidia Pharma USA Inc.2$33
Pacira Therapeutics, Inc.1$31
Integra Lifesciences Corporation1$22
Electronic Waveform Lab, Inc.1$18
Smith+Nephew1$13
Biohaven Pharmaceuticals, Inc.1$12

How this compares

Too few sports medicine providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$307,140
Medicare patients
737
Services billed
7,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide102$265,758
Teriparatide50$145,236
Celecoxib53$1,733
Ibandronate Sodium33$1,452
Alendronate Sodium164$1,255
Methylprednisolone193$1,197
Ultra-Fine Micro Pen NeedlePen Needle, Diabetic25$587
Lidocaine11$547
Ultra-Fine Short Pen NeedlePen Needle, Diabetic12$282
Prednisone84$244
Oxycodone Hcl19$197
Gabapentin26$190
Meloxicam40$180
Tramadol Hcl27$82

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$474$265,758102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sports medicine providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other sports medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →